Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...

Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the ...

Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants ...

Eli Lilly said Wednesday it will invest $27 billion to build four new manufacturing plants in the United States as the pharmaceutical giant grapples with the threat of drug import duties from the ...

In addition, due for completion in 2027 is the company’s $1.7 billion plant in Concord, North Carolina. All told, Eli Lilly has tallied up about $23 billion in U.S. manufacturing commitments in ...

With this latest announcement, Lilly has committed to investing more than $50 billion in U.S. manufacturing since 2020.

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United States ...

Eli Lilly (LLY) announces it will invest $27 billion in four new manufacturing sites in the US. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to break down the news.

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United States, ...

Eli Lilly and Co. Wednesday announced plans to build four pharmaceutical manufacturing sites in the ... Lilly will invest $27 billion in the four plants, the Indianapolis drugmaker announced ...

The new plants will be built over the next five years, and are expected to create more than 3,000 jobs for skilled workers.